Clinical trials: Multiple Sclerosis (Relapsing Remitting)
All Multiple Sclerosis Patients
Fatigue Treatment Using Provigil
To determine whether therapy with Modafinal(Provigil) is safe and effective in fatigue in MS Patients
- Trial name
- NCT00220506
- Testing
- Provigil
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Relapsing-Remitting
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
- Trial name
- NCT00242177
- Testing
- ACTOS (Pioglitazone)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Illinois at Chicago
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis
The aim of this study is the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate)on retinoic acid receptor and retinoic x receptor expression.
- Trial name
- RAR (NCT01705457)
- Testing
- Dietary Supplement: vitamin A
- Where
- Iran
- Volunteers
- 20 people
- Sponsor
- Tehran University of Medical Sciences
Multiple Sclerosis - Relapsing Remitting, Clinically Isolated Syndrome, CNS Demyelinating
DTI in Children With Multiple Sclerosis
This is a prospective, non-randomised, non-blinded, single center study of children and adolescents with multiple sclerosis and clinically isolated syndrome to detect differences or early changes in diffusion-weighted imaging…
- Trial name
- NCT02361697
- Testing
- DTI-MRI
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Relapsing-Remitting Multiple Sclerosis
Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
This study will be a single center, retrospective, pilot study to determine the effect of Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total lymphocyte counts, grade of lymphopenia, Cluster of…
- Trial name
- NCT03284970
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Remitting Multiple Sclerosis
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
The aim of this study is to study the comparison between the effects of supplementation with 25000 IU preformed vitamin A (retinyl palmitate) or placebo for 6 months on immune system and Th1/Th2 balance in patients with Multiple…
- Trial name
- NCT01225289
- Testing
- Vitamin A
- Where
- 2 sites in Iran
- Volunteers
- 36 people
- Sponsor
- Tehran University of Medical Sciences
MS Patient With Relpasing Remitting Attacks
Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment
The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients
- Trial name
- NCT00674141
- Testing
- Dexamethasone soduim phosphate
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Hadassah Medical Organization
Multiple Sclerosis, Relapsing-Remitting
Photobiomodulation Therapy in Persons With Multiple Sclerosis
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
- Trial name
- NCT03691766
- Testing
- Photobiomodulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marquette University
Relapsing Remitting MS (RRMS), Secondary Progressive MS (SPMS)
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors.
- Trial name
- NCT01233245
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 15 sites in Czechia, France and 13 more
- Volunteers
- 1,077 people
- Sponsor
- Bayer
Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
- Trial name
- NCT00035529
- Testing
- BMS 188667 (Abatacept)
- Where
- 10 sites in United States
- Sponsor
- Bristol-Myers Squibb
Relapsing-Remitting Multiple Sclerosis
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
The primary objective of the study is to determine which baseline and yearly response factors (clinical and para clinical) predict overall disease-free status at Month 12 and Month 24, and clinical disease-free status in…
- Trial name
- STRIVE (NCT01485003)
- Testing
- natalizumab
- Where
- 44 sites in United States
- Volunteers
- 231 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple…
- Trial name
- CLOCK-MS (NCT03963375)
- Testing
- Cladribine
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Gregory Wu
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS) Relapsing Remitting
Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis
The purpose of this study is to assess the immediate effects of a commercially available non-FDA regulated powered hip flexion assist device (Hypershell X, Shenzhen, China) on walking ability in persons with MS.
- Trial name
- NCT07724093
- Testing
- Powered Hip Flexion Orthosis (Hypershell X)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Dayton
Relapsing Remitting Multiple Sclerosis
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT04711148
- Testing
- orelabrutinib
- Where
- 42 sites in United States, China and 2 more
- Volunteers
- 160 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis
Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis
The goal of this clinical trial is to learn whether a structured lifestyle program can improve health and wellbeing in people living with multiple sclerosis (MS).
- Trial name
- HEAL-MS (NCT07589062)
- Testing
- Multi-Domain Lifestyle Intervention
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- New York University Abu Dhabi